|Table of Contents|

Difference of expression and clinical significance of mismatch repair proteins in upper tract urothelial carcinoma and bladder urthelial carcinoma tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4497-4503
Research Field:
Publishing date:

Info

Title:
Difference of expression and clinical significance of mismatch repair proteins in upper tract urothelial carcinoma and bladder urthelial carcinoma tissues
Author(s):
TIAN Wei1; YIN Xique1; YANG Xu1; LI Yan1; WANG Hui2; TIAN Ziyuan3; ZHANG Guanjun4
1.Department of Pathology;2.Department of Urology,No.215 Hospital of Shaanxi Nuclear Industry,Shaanxi Xianyang 712035,China;3.Grade 2022,Eight-year Program Student of Stomatology,Air Force Medical University,Shaanxi Xi'an 710038,China;4.Department of Pathology,the First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
upper tract urothelial carcinoma; bladder urthelial carcinoma; mismatch repair protein; immunohistochemical; prognosis; retrospective studies
PACS:
R737.15
DOI:
10.3969/j.issn.1672-4992.2024.23.012
Abstract:
Objective:To analyse the difference and significance of mismatch repair protein(MMR) expression between UTUC and BUC.Methods:From December 2010 to December 2022,the clinicopathological data of 309 cases of UTUC and BUC diagnosed in the 215 hospital of Shaanxi Nuclear Industry were analyzed retrospectively.MLH1,PMS2,MSH2 and MSH6 were selected by immunohistochemical staining.The mismatch repair-defective(dMMR) between UTUC and BUC groups was investigated and analyzed statistically.Results:The dMMR occurred in 11 of 309 urothelial carcinoma patients,the rate was 3.6%（11/309）.The results of single factor analysis showed that the incidence of dMMR in UTUC and BUC was significantly different(P＜0.05).The expression rate of dMMR in UTUC group was 7.3%,in BUC group was 1.5%.In addition,there were statistical differences in gender maximun,tumor diameter,histological grade,number of tumors,T stage,N stage and cancer embolus（all P＜0.05）.Logistic multivariate analysis found that gender,number of tumors,T stage,N stage and dMMR were independent factors related to UTUC （all P＜0.05）.Kaplan-Meier survival analysis showed that the OS of the dMMR patients in the UTUC group was significantly higher than that of mismatch repair-proficient(pMMR) patients（P=0.048）,but in all UC and in the BUC group,there was no significant difference in OS between dMMR patients and pMMR patients（P=0.182,P=0.682 respectively）.Further research found that there was a significant difference in recurrence or metastasis between dMMR and pMMR patients in UTUC(P=0.036).Conclusion:The incidence of dMMR in UTUC is significantly higher than that in BUC,and it only suggests a better prognostic effect in UTUC,but no prognostic indicator in BUC.

References:

［1］FREDDIE BRAY,MATHIEU LAVERSANNE,HYUNA SUNG,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］REBECCA L SIEGEL,ANGELA N GIAQUENTO,AHMEDIN JEMAL.Cancer statistics,2024 ［J］.CA Cancer J Clin,2024,74(1):12-49.
［3］CHEN XP,XIONG GY,LI XS,et al.Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma:experience from a nationwide high-volume centre in China ［J］.BJU Int,2013,112(7):17-24.
［4］MORGAN ROUPRET,THOMAS SEISEN,ALISON J BIRTLE,et al.European association of urology guidelines on upper urinary tract urothelial cell carcinoma:2023 Update ［J］.Eur Urol,2023,84(1):49-64.
［5］J ALFRED WITJES,HARMAN MAX BRUINS,RICHARD CATHOMAS,et al.European association of irology guidelines on muscle-invasive and metastatic bladder cancer.Summary of the 2020 gudelines ［J］.Eur Urol,2021,79:82-104.
［6］ANDREA NECCHI,RUSSELL MADISON,SUMANTA K PAL,et al.Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma ［J］.Eur Urol Focus,2021,7(6):1339-1346.
［7］MARIA R,MIA GEBAUER M,CHRISTINA T.Immunohistochemical screening of upper tact urothelial carcinomas for lynch syndrome diagnostics:A systematic review ［J］.Urology,2022,165:44-53.
［8］FRANCOIS AUDENT,SUMIT ISHARWAL,EUGENE K CHA,et al.Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma ［J］.Clin Cancer Res,2019,25(3):967-976.
［9］HOLLY L HARPER,JESSE K MCKENNEY,BRANDIE HEALD,et al.Upper tract urothelial carcinomas:frequency of association with mismatch repair protein loss and lynch syndrome ［J］.Mod Pathol,2017,30(1):146-156.
［10］MATTHEW GEORGE GAYHART,NICOLE JOHNSON,ASIT PAUL,et al.Universal mismatch repair protein screening in upper tract urothelial carcinoma ［J］.Am J Clin Pathol,2020,154:792-801.
［11］YANG KY,YU W,LIU HH,et al.Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder ［J］.Oncologist,2021,26(8):e1395-e1405.
［12］JUAN RUIZ-BANOBRE,AJAY GOEL.DNA mismatch repair deficiency and immune chechpoint inhibitors in gastrointestinal cancers ［J］.Gastroenterology,2019,156(4):890-903.
［13］ANNA MARIA VALENTINI,RAFFAELE ARMENTANO,MICHELE PIRRELLI,et al.Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system:the state of the art ［J］.Cancer Treat Rev,2006,32(8):607-618.
［14］S AEBI,D FINK,R GORDON,et al.Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells ［J］.Clin Cancer Res,1997,3(10):1763-1767.
［15］LU EZ,ILGIZ GAREEV,YUAN CHAO,et al.The mechanisms of current platinum anticancer drug resistance in the glioma ［J］.Current Pharmaceutical Design,2022,28(23):1863-1869.
［16］A FEDIER,VA SCHWARZ,H WALT,et al.Resistance to topoisomerase poisons due to loss of DNA mismatch repair ［J］.Int Cancer,2001,93(4):571-576.
［17］RAMUNAS JANAVICIUS,DOVILE MATIUKAITE,ARTURAS JAKUBAUSKAS,et al.Microsatellite instability detection by high-resolution melting analysis ［J］.Clin Chem,2010,56(11):1750-1757.
［18］JAMES WF CATTO,ABDEL-RAHMENE AZZOUZI,NAJLA AMIRA,et al.Distinct patterns of microsatellite instability are seen in tumours of the urinary tract ［J］.Oncogene,2003,22(54):8699-8706.
［19］KAJSA M ERICSON,ANNA P ISINGER,BJORN L ISFOSS,et al.Low frequency of defective mismatch repair in a population-based series of uper urothelial carcinoma ［J］.BMC Cancer,2005,5:23.
［20］FRIEDERIKE K,PAMELA LS,REINER S,et al.Frequency of microsatellite instability(MSI) in upper tract urothelial carcinoma:comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected,multi-institutional cohort ［J］.Clin Pathol,2023,76(2):126-132.
［21］MICHAEL MB,JOHN MK,JOHN LM,et al.Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease［J］.J Immunother Cancer,2018,6(1):35.
［22］MARIA S PINO,DANIEL C CHUNG.Microsatellite instability in the management of colorectal cancer ［J］.Expert Rev Gastroenterol Hepatol,2011,5(3):385-399.
［23］郑超，王玻玮，才层，等.结直肠癌组织MSI状态及其与临床病理参数之间的相关性 ［J］.现代肿瘤医学,2021,29(17):3053-3056. ZHENG Chao,WANG Bowei,CAI Ceng,et al.Correlation between MSI status and clinicopathologic features in colorectal cancer tissue［J］.Modern Oncology,2021,29(17):3053-3056.
［24］ENAMI KANEKO,NAOKI SATO,TAE SUGAWARA,et al.MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial cancinomas ［J］.Gynecol Oncol,2021,32(6):e79.
［25］许梅海,覃永平,尹家瑜,等.直肠癌复发转移与错配修复蛋白表达的相关性研究［J］.海南医学,2022,33(12):1501-1504. XU Meihai,QIN Yongping,YIN Jiayu,et al.Correlation between recurrence and metastasis of rectal cancer and expression of mismatch repair protein ［J］.Hainan Med,2022,33(12):1501-1504.
［26］钟丽,刘茜茜，曲颜丽.错配修复蛋白在左、右半结肠癌组织中的表达差异及其临床意义［J］.现代肿瘤医学，2023,30(01):126-129. ZHONG Li,LIU Qianqian,QU Yanli.Difference of expression and clinical significance of mismatch repair proteins in left and right colon cancer tissues［J］.Modern Oncology,2023,30(01):126-129.
［27］邵文裕,董悠婷,吕巧英,等.不同分子特征对子宫内膜癌和子宫内膜非典型增生患者保留生育功能治疗结局的影响［J］.中华妇产科杂志,2023,58(10):742-754. SHAO Wenyu,DONG Youting,LYU Qiaoying,et al.Fertility-preserving treatment outcomes inendometrial cancer and atypical hyperplasia patients with different molecular profiles ［J］.Chin J Obstet Gynecol,2023,58(10):742-754.
［28］JENNIFER Y JU,ANNE M MILLS,MANI S MAHADVAN,et al.Universal lynch syndrome screening should be performed in all upper tract urothelial carcinomas ［J］.Am Surg Pathol,2018,42(11):1549-1555.

Memo

Memo:
陕西省核工业二一五医院2023年院级科研课题项目（编号：215KYJJ-202309）
Last Update: 2024-11-01